Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
| Market Cap | 1.16B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -430.80M |
| Shares Out | 68.32M |
| EPS (ttm) | -7.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 311,931 |
| Open | 17.14 |
| Previous Close | 17.19 |
| Day's Range | 16.69 - 17.18 |
| 52-Week Range | 5.54 - 26.64 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 24.80 (+46.49%) |
| Earnings Date | Nov 8, 2023 |
About BHVN
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric i... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for BHVN stock is "Strong Buy." The 12-month stock price forecast is $24.8, which is an increase of 46.49% from the latest price.
News
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
- Taldefgrobep alfa is the only myostatin inhibitor in clinical development that targets both myostatin and activin A signaling, two key regulators of muscle mass and adipose tissue - RESILIENT, the p...
Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies
Examination of EEG in healthy subjects administered single doses of BHV-7000 confirmed central nervous system (CNS) activity consistent with effects observed with other antiseizure medications. EEG re...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN).
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
Taldefgrobep alfa, in Phase 3 global clinical development for Spinal Muscular Atrophy, granted EU Orphan Drug Designation in addition to previously receiving Fast Track and Orphan Drug Designation in ...
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023 Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous...
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
NEW HAVEN, Conn. , July 27, 2023 /PRNewswire/ -- Biohaven Ltd.
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
Submitted a new drug application (NDA) for troriluzole in Spinocerebellar Ataxia Type 3 (SCA3) to U.S. FDA in 2Q2023, marking the team's fourth NDA in approximately 3 years Released additional data fr...
Biohaven to Present R&D Day at Yale School of Management
NEW HAVEN, Conn. , May 25, 2023 /PRNewswire/ -- Biohaven Ltd.
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China) Appointed Nick Kozauer, M.D. a...
Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy
NEW HAVEN, Conn. , April 17, 2023 /PRNewswire/ -- Biohaven Ltd.
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global (ex-China) rights; Phase 1 clinical trial initiation an...
Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders
Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse cla...
Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
BHV-7000 differs pharmacologically and structurally from other known Kv7 compounds in development BHV-7000 demonstrates potent anti-seizure activity without effects on neurobehavior in preclinical mod...
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
- Taldefgrobep alfa, a myostatin-targeting biologic investigational agent, in Phase 3 development to increase muscle mass for Spinal Muscular Atrophy patients now granted Fast Track in addition to pr...
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
NEW HAVEN, Conn. , Jan. 6, 2023 /PRNewswire/ -- Biohaven Ltd.
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor
PALO ALTO, Calif.--(BUSINESS WIRE)--Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon ...
Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
Biohaven Ltd. launched post-closing of the Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW HAVEN, Conn. , Oct. 25, 2022 /PRNewswire/ -- Biohaven Ltd.
Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
Biohaven advances development of its extracellular target degrader platform technology (MoDEs™) for therapies across a variety of diseases including neuroscience, immunology and oncology Through its c...
Biohaven Announces Pricing of Public Offering of Common Shares
NEW HAVEN, Conn. , Oct. 20, 2022 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Launch of Public Offering of Common Shares
NEW HAVEN, Conn. , Oct. 18, 2022 /PRNewswire/ -- Biohaven Ltd.
Biohaven CEO on on Pfizer's acquisition of the company
Cramer spoke with Biohaven CEO Vlad Coric on Tuesday.
Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients
Broad therapeutic research and development portfolio includes more than 13 clinical and pre-clinical programs with a focus on neuroscience and rare disorders including epilepsy, pain and mood disorder...
Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)
NEW HAVEN, Conn. , Sept. 29, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Announces Record Date for Anticipated Spin-Off
NEW HAVEN, Conn. , Sept. 18, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.